NCT06501079 Dexamethasone Versus Mg Added to Bupivacaine Used in ESPB for Perioperative Pain Control in Patients Undergoing Unilateral Nephrectomy
| NCT ID | NCT06501079 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Renal Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2024-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2024-05-01 with a primary completion date of 2024-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aim of the study: The current study aims to compare the effect of adding dexamethasone versus magnesium sulfate to bupivacaine in ultrasound-guided erector spinae plane block on the severity of postoperative pain. Primary Objectives: \- To compare the effect of ESPB without additives to the effect of adding dexamethasone and to the impact of adding magnesium sulfate in the form of post-operative morphine consumption
Eligibility Criteria
Inclusion Criteria: * Adult (18 - 65) * Patients undergoing unilateral nephrectomy * ASA II / III Exclusion Criteria: * Patient refusal * Age less than 18 years * Allergy to any of the studied medications * Mid line incision * Bilateral nephrectomy * Distorted anatomy of the back (e.g. kyphoscoliosis) * Known neurologic disorders, psychiatric disorder or chronic pain * Local infection * Hemodynamic instability
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06501079 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Renal Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06501079 currently recruiting?
Yes, NCT06501079 is actively recruiting participants. Contact the research team at ams21787arif@hotmail.com for enrollment information.
Where is the NCT06501079 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06501079 clinical trial?
NCT06501079 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 78 participants.